LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma

Table 1 Associations between LZTS2 promoter methylation and LSCC patient clinicopathological characteristics

Variable	Number	Mean ± SD	P value
Gender
Female	4	20.11 ± 6.39	0.364
Male	92	27.37 ± 15.80	0.364
Age
≥ 60	49	24.05 ± 14.15	0.995
< 60	47	27.07 ± 17.09	0.995
Smoking behavior
Yes	78	28.57 ± 15.94	0.049
No	18	20.56 ± 12.21	0.049
Histological classification
Well	45	27.98 ± 15.35	0.590
Moderately/poorly	51	26.25 ± 15.88	0.590
T classification
T 1 + 2	57	23.26 ± 13.47	0.003
T 3 + 4	39	32.62 ± 12.90	0.003
Clinical stage
Stage I + II	45	22.44 ± 11.64	0.005
Stage III + IV	51	31.14 ± 17.48
Lymph metastasis
Yes	33	32.85 ± 18.62	0.019
No	63	24.03 ± 12.87	0.019

LZTS2 promoter methylation levels were significantly elevated in advanced stage and advanced T classified patients, in patients who were smokers, as well as cases with lymph node metastasis. Italicized entries indicate statistical significance

ISSN: 1477-7819